Chemours (CC) PT Lowered to $20 at Truist Securities

Truist Securities analyst Peter Osterland lowered the price target on Chemours (NYSE: CC) to $20.00 (from $22.00) while maintaining a Buy rating.

The analyst commented: "We have updated our estimates for CC post-1Q25 earnings and maintain our Buy rating, lowering our price target to $20 from $22. While 1H earnings for TiO2 are tracking below consensus, CC does expect full year earnings growth for the segment as cost cuts kick in more significantly in 2H. Opteon growth continues to be a standout, with TSS margins poised to continue in the 30%+ range this year, and what appears to be continued progress readying the company for commercialization of its data center cooling product. While we believe the announced dividend cut has been a focus, we note CC does expect a return to positive FCF in 2Q and through the remainder of the year."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49